These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 12384808)
1. A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells. Epel M; Ellenhorn JD; Diamond DJ; Reiter Y Cancer Immunol Immunother; 2002 Nov; 51(10):565-73. PubMed ID: 12384808 [TBL] [Abstract][Full Text] [Related]
2. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363 [TBL] [Abstract][Full Text] [Related]
3. Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity. Reiter Y; Di Carlo A; Fugger L; Engberg J; Pastan I Proc Natl Acad Sci U S A; 1997 Apr; 94(9):4631-6. PubMed ID: 9114042 [TBL] [Abstract][Full Text] [Related]
4. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. Denkberg G; Cohen CJ; Lev A; Chames P; Hoogenboom HR; Reiter Y Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9421-6. PubMed ID: 12093904 [TBL] [Abstract][Full Text] [Related]
5. Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes. Lev A; Novak H; Segal D; Reiter Y J Immunol; 2002 Sep; 169(6):2988-96. PubMed ID: 12218113 [TBL] [Abstract][Full Text] [Related]
6. Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes. Oved K; Lev A; Noy R; Segal D; Reiter Y Cancer Immunol Immunother; 2005 Sep; 54(9):867-79. PubMed ID: 15906027 [TBL] [Abstract][Full Text] [Related]
7. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant. McArdle SE; Rees RC; Mulcahy KA; Saba J; McIntyre CA; Murray AK Cancer Immunol Immunother; 2000 Oct; 49(8):417-25. PubMed ID: 11043848 [TBL] [Abstract][Full Text] [Related]
8. A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity. Card KF; Price-Schiavi SA; Liu B; Thomson E; Nieves E; Belmont H; Builes J; Jiao JA; Hernandez J; Weidanz J; Sherman L; Francis JL; Amirkhosravi A; Wong HC Cancer Immunol Immunother; 2004 Apr; 53(4):345-57. PubMed ID: 14610621 [TBL] [Abstract][Full Text] [Related]
9. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. Hernández J; Lee PP; Davis MM; Sherman LA J Immunol; 2000 Jan; 164(2):596-602. PubMed ID: 10623800 [TBL] [Abstract][Full Text] [Related]
10. Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells. Liu X; Peralta EA; Ellenhorn JD; Diamond DJ Cancer Res; 2000 Feb; 60(3):693-701. PubMed ID: 10676655 [TBL] [Abstract][Full Text] [Related]
11. Recruitment of Oligoclonal Viral-Specific T cells to Kill Human Tumor Cells Using Single-Chain Antibody-Peptide-HLA Fusion Molecules. Noy R; Haus-Cohen M; Oved K; Voloshin T; Reiter Y Mol Cancer Ther; 2015 Jun; 14(6):1327-35. PubMed ID: 25852061 [TBL] [Abstract][Full Text] [Related]
12. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells. Yu Z; Liu X; McCarty TM; Diamond DJ; Ellenhorn JD J Surg Res; 1997 May; 69(2):337-43. PubMed ID: 9224403 [TBL] [Abstract][Full Text] [Related]
13. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Epel M; Carmi I; Soueid-Baumgarten S; Oh S; Bera T; Pastan I; Berzofsky J; Reiter Y Eur J Immunol; 2008 Jun; 38(6):1706-20. PubMed ID: 18446790 [TBL] [Abstract][Full Text] [Related]
14. Functional evidence for TCR-intrinsic specificity for MHCII. Parrish HL; Deshpande NR; Vasic J; Kuhns MS Proc Natl Acad Sci U S A; 2016 Mar; 113(11):3000-5. PubMed ID: 26831112 [TBL] [Abstract][Full Text] [Related]
15. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies. Cohen CJ; Sarig O; Yamano Y; Tomaru U; Jacobson S; Reiter Y J Immunol; 2003 Apr; 170(8):4349-61. PubMed ID: 12682272 [TBL] [Abstract][Full Text] [Related]
16. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Lev A; Denkberg G; Cohen CJ; Tzukerman M; Skorecki KL; Chames P; Hoogenboom HR; Reiter Y Cancer Res; 2002 Jun; 62(11):3184-94. PubMed ID: 12036932 [TBL] [Abstract][Full Text] [Related]
17. Specificity and binding properties of a single-chain T cell receptor. Schlueter CJ; Schodin BA; Tetin SY; Kranz DM J Mol Biol; 1996 Mar; 256(5):859-69. PubMed ID: 8601837 [TBL] [Abstract][Full Text] [Related]
18. Construction of a functional disulfide-stabilized TCR Fv indicates that antibody and TCR Fv frameworks are very similar in structure. Reiter Y; Kurucz I; Brinkmann U; Jung SH; Lee B; Segal DM; Pastan I Immunity; 1995 Mar; 2(3):281-7. PubMed ID: 7697545 [TBL] [Abstract][Full Text] [Related]
19. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3. Benhar I; Pastan I J Biol Chem; 1995 Oct; 270(40):23373-80. PubMed ID: 7559495 [TBL] [Abstract][Full Text] [Related]
20. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. Cohen CJ; Denkberg G; Lev A; Epel M; Reiter Y J Mol Recognit; 2003; 16(5):324-32. PubMed ID: 14523945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]